Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Jun 01, 2023	Post-effective amendment to an S-8 filing	S-8 POS	Registration Statements	0001104659-23-067090.pdf 0001104659-23-067090.rtf View HTML
Jun 01, 2023	Post-effective amendment to an S-8 filing	S-8 POS	Registration Statements	0001104659-23-067092.pdf 0001104659-23-067092.rtf View HTML
Jun 01, 2023	Post-effective amendment to an S-8 filing	S-8 POS	Registration Statements	0001104659-23-067095.pdf 0001104659-23-067095.rtf View HTML
Jun 01, 2023	Post-effective amendment to an S-8 filing	S-8 POS	Registration Statements	0001104659-23-067098.pdf 0001104659-23-067098.rtf View HTML
Jun 01, 2023	Post-effective amendment to an S-8 filing	S-8 POS	Registration Statements	0001104659-23-067097.pdf 0001104659-23-067097.rtf View HTML
Mar 22, 2022	Post-effective amendment to an S-Type filing	POS AM	Registration Statements	0001193125-22-081689.pdf 0001193125-22-081689.rtf 0001193125-22-081689.xls View HTML
Jun 01, 2023	Post-effective amendment to an S-Type filing	POS AM	Registration Statements	0001104659-23-067102.pdf 0001104659-23-067102.rtf View HTML
Jun 01, 2023	Post-effective amendment to an S-Type filing	POS AM	Registration Statements	0001104659-23-067103.pdf 0001104659-23-067103.rtf View HTML
Jun 01, 2023	Post-effective amendment to an S-Type filing	POS AM	Registration Statements	0001104659-23-067104.pdf 0001104659-23-067104.rtf View HTML
Mar 30, 2020	Pre-effective amendment to an S-3 filing	S-3/A	Registration Statements	0001193125-20-090086.pdf 0001193125-20-090086.rtf 0001193125-20-090086.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.